[1]李 梅,宋娟荣,翟鹏涛,等.载药微球在原发性肝癌TACE治疗中疗效及安全性分析[J].介入放射学杂志,2021,30(02):186-190.
 LI Mei,SONG Juanrong,ZHAI Pengtao,et al.Transcatheter arterial chemoembolization with drug-eluting beads in the treatment of primary hepatocellular carcinoma: analysis of its curative effect and safety[J].journal interventional radiology,2021,30(02):186-190.
点击复制

载药微球在原发性肝癌TACE治疗中疗效及安全性分析()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年02
页码:
186-190
栏目:
临床研究
出版日期:
2021-02-25

文章信息/Info

Title:
Transcatheter arterial chemoembolization with drug-eluting beads in the treatment of primary hepatocellular carcinoma: analysis of its curative effect and safety
作者:
李 梅 宋娟荣 翟鹏涛 穆旭东 姚 乐
Author(s):
LI Mei SONG Juanrong ZHAI Pengtao MU Xudong YAO Le.
Department of Minimally- Invasive Intervention, Shaanxi Provincial Cancer Hospital, Xi’an, Shaanxi Province 710061, China
关键词:
【关键词】 载药微球 罂粟乙碘油 原发性肝癌 肝动脉化疗栓塞术
文献标志码:
A
摘要:
【摘要】 目的 探讨在TACE治疗原发性肝癌中载药微球(DEB)的应用的近期疗效及安全性。方法 回顾性分析原发性肝癌101例,按照所用栓塞剂不同,分为DEB-TACE组(49例)和cTACE组(52例), DEB-TACE组应用CalliSphere载药微球进行TACE治疗。cTACE组应用罂粟乙碘油行TACE治疗,比较两组患者近期疗效,甲胎蛋白、肝功能变化和术后并发症。结果 术后第3天两组ALB均较术前降低,差异有统计学意义(P<0.05),ALT、AST、TBIL、DBI均较术前增高,差异有统计学意义(P<0.05)。术后1个月,DEB-TACE组和cTACE组客观缓解率分别为69.4%与55.8%,疾病控制率分别为93.9%与88.5%。术后3个月,两组客观缓解率分别为59.2%与42.3%,疾病控制率分别为87.8%与76.9%,差异均无统计学意义(P>0.05)。术后6个月,两组客观缓解率分别为53.1%与30.8%,差异有统计学意义(P<0.05),疾病控制率分别为79.6%与69.2%,差异无统计学意义(P>0.05)。术后6个月AFP≥200 ng/mL,DEB-TACE组为25.8%,cTACE组为56.3%,差异有统计学意义(P<0.05)。术后两组均出现轻度的栓塞后综合征,经对症治疗后症状消失,两组分别相比,差异均无统计学意义(P>0.05),未见肾衰竭、感染、骨髓抑制等严重并发症。结论 DEB-TACE治疗原发性肝癌近期疗效肯定,安全性好,值得临床推广。

参考文献/References:

[1] Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin- eluting beads and bland embolization with beadblock for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2010, 33: 541-551.
[2] Zhang S,Huang C,Li Z,et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulssions and CalliSpheres beads in rabbit livers[J]. Drug Deliv, 2017, 24: 1011-1017.
[3] Zurstrassen CE,Gireli LPO,Tyng CJ,et al. Safety and efficacy of hepa sphere 50-100 um in the treatment of hepatocellular carcinoma[J]. Minim Invasive Ther Allied Technol, 2017, 26:212-219.
[4] Qin S, Bai Y, Lim HY, et al. Randomized,multicenter,openlabel study of oxaliplation plus fluorouracil/lencovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31: 3501-3508.
[5] Qin SK, Cheng Y, Liang J, et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study[J]. Oncologist, 2014, 19: 1169-1178.
[6] Gong XL, Yang LQ, Qin SK. Advances in the anti-tumor effect of oxaliplatin and its new immunological mechanism[J]. J Clin Oncol, 2016, 21: 1031-1037.
[7] 龚新雷,杨柳青,秦叔逵. 奥沙利铂抗肿瘤作用及其免疫学新机制的研究进展[J]. 临床肿瘤学杂志, 2016, 21:1031-1037.
[8] Omata M, Lesmana LA, Tateishi R, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4: 439-474.
[9] European Association for the Study of The Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepato-cellular carcinoma[J]. J Hepatol, 2012, 56: 908-943.
[10] Liu YS, Ou MC, Tsai YS, et al. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol- doxorubicin versus doxorubicin loaded beads for the treatment of hepatocellular carcinoma[J]. Korean J Radiol, 2015, 16: 125-132.
[11] Hao MZ, Lin HL, Chen QZ, et al. Safety and efficacy of transca-theter arterial chenoembolization with embospheres in treatment of hepatocellular carcinoma[J]. J Dig Dis, 2017, 18: 31-39.
[12] Zuo MX, Huang JH. The history of interventional therapy for liver cancer in China[J]. J Intervent Med, 2018, 1: 70-76.
[13] Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolizationg in the treatment of hepatocellular carcinoma: results of the PRECISION Ⅴ study[J]. Cardiovasc interevent Radiol, 2010, 33: 41-52.
[14] 赵 倩,颜志平. 载药微球经导管动脉化疗栓塞治疗肝癌研究进展[J]. 介入放射学杂志, 2017, 26:1052-1056.
[15] 陈 刚,张 鼎,应亚草,等. 国产载药微球经动脉化疗栓塞治疗不可切除原发性肝癌的临床研究[J]. 浙江大学学报(医学版), 2017, 46:44-51.
[16] Cucchetti A, Trevisani F, Cappelli A, et al. Cost- effectiveness of doxorubicin- eluting beads versus conventional trans- arterial chemo- embolization for hepatocellular carcinoma[J]. Dig Liver Dis, 2016, 48: 798- 805.
[17] Lau WY, Lai ECH. Loco- regional intervention for hepatocellular carcinoma[J]. J Intervent Med, 2019, 2: 43- 46.
[18] 周官辉,孙军辉,张岳林,等. HepaSphere载药微球栓塞治疗不可切除肝癌15例[J]. 介入放射学杂志, 2015, 24:869-872.

相似文献/References:

[1]王辅明,刘敬禹,杨继金.载药微球治疗腹膜后平滑肌肉瘤术后肝转移1例 [J].介入放射学杂志,2018,27(04):308.
 WANG Fuming,LIU Jingyu,YANG Jijin.Drug- eluting beads for the treatment of hepatic metastasis following surgery of retroperitioneal leiomyosarcoma: report of one case[J].journal interventional radiology,2018,27(02):308.
[2]纪坤,李臻,李鑫,等.载药微球化疗栓塞治疗巨大扁桃体鳞癌1例 [J].介入放射学杂志,2020,29(02):219.
 JI Kun,LI Zhen,LI Xin,et al.Successful treatment of giant tonsillar squamous cell carcinoma with chemoembolization by using drug-eluting beads: report of one case[J].journal interventional radiology,2020,29(02):219.
[3]姚远方,高 飞,张雪松,等.载药微球加载贝伐珠单抗介入栓塞治疗兔VX2肝癌的抗血管生成效果[J].介入放射学杂志,2021,30(03):254.
 YAO Yuanfang,GAO Fei,ZHANG Xuesong,et al.The anti-angiogenesis effect of interventional embolization using drug-loaded microspheres with bevacizumab in treating rabbit VX2 hepatocellular carcinoma[J].journal interventional radiology,2021,30(02):254.
[4]吴伟达,彭建扬,翁志成,等.载药微球栓塞治疗膀胱癌伴出血16例[J].介入放射学杂志,2022,31(05):484.
 WU Weida,PENG Jianyang,WENG Zhicheng,et al.Drug-eluting beads embolization for the treatment of bladder cancer associated with hemorrhage: preliminary results in 16 patients[J].journal interventional radiology,2022,31(02):484.
[5]张 杰,张景俊.载药微球TACE联合全身系统治疗方案在消化道恶性肿瘤肝转移患者中的疗效观察 [J].介入放射学杂志,2022,31(10):995.
 ZHANG Jie,ZHANG Jingjun..Drug-eluting beads transcatheter arterial chemoembolization plus systematic chemotherapy in treating patients with digestive tract cancer complicated by liver metastasis: observation of its clinical efficacy[J].journal interventional radiology,2022,31(02):995.

备注/Memo

备注/Memo:
(收稿日期:2019-11-07)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-02-22